Prolactin (PRL) is an immunomodulatory hormone that may promote LP, as has been documented in other autoimmune disorders, such as systemic lupus erythematosus, rheumatoid arthritis, and psoriasis. PRL has multiple immune-stimulatory effects and promotes the development of such autoimmune disorders. Prolactin and uric acid may serve as biomarkers of disease activity in lichen planus. The aim of the present study was to evaluate the roles of depression, stress, and anxiety in LP, as well as serum levels of UA and PRL as potential biomarkers of disease activity and compare these findings with those of the control group. Thirty-nine patients clinically diagnosed with oral LP (study group) and 39 age-and sex-matched controls (control group) were selected in this study. Serum UA and PRL levels were measured. The Depression Anxiety Stress Scale-21 was used for psychometric evaluation of LP patients and controls. Serum UA level was found to be significantly higher in the control group as well as during the remission phase of disease in the study. There was no significant difference in serum PRL levels between cases and controls. Depression and stress scores were higher in the study group.
Introduction
Lichen planus (LP) is a chronic, autoimmune, mucocutaneous, psychosocial disease that usually presents in middle-aged females and primarily affects the oral mucosa, skin, genital mucosa, scalp, and nails. LP is estimated to affect 0.5 to 2.0% of the general population, with a prevalence of 0.5% in the Japanese population, 1.9% in the Swedish population, 2.6% in the Indian population, and 0.38% in the Malaysian population (relatively uncommon). Oral LP can clinically present in various forms, including reticular, papular, plaque-like, atrophic, erosive, and bullous types (1, 2) . Cell-mediated immunity, especially cytotoxic CD8+ cell responses on modified keratinocytes carrying specific surface antigens, plays a major role in the pathogenesis of oral LP, resulting in degeneration of the basal epithelial layer (3) .
It has been suggested that increased production of reactive oxygen species (ROS) and lipid peroxides may play roles in the pathogenesis of LP. In LP, inflammatory cellular infiltrate, which mainly consists of CD4+ lymphocytes, is a well-known source of ROS (4) . In high concentrations, ROS cause damage to endothelial cells and subsequently upregulate intercellular adhesion molecule 1 leading to the recruitment of T lymphocytes (5) . Also, oxidative stress may activate nuclear factor kappa-light-chain-enhancer of activated B cells, which is an important transcription factor of various cytokine genes that include interleukin (IL)-2 and tumor necrosis factor (TNF)-α, as well as the major histocompatibility complex class I gene and the IL-2 receptor gene. H 2 O 2 and superoxide anions may be produced by TNF-α in epidermal keratinocytes (6) . Also, oxidative stress is involved in both pro-and anti-apoptotic signaling in response to TNF-α (7) . Further, oxidative stress and increased inflammatory mediators release effector molecules, including granzyme, which can promote local tissue damage (8) .
Antioxidants, like some enzymes, vitamins, uric acid (UA), etc., participate in primary defense mechanisms against oxidative stress (9, 10) . UA is an important antioxidant in plasma that scavenges ROS and chelates metal ions (11, 12) . Thus, monitoring of serum UA levels as an indicator of antioxidant defense (oxidative balance) could be an important clinical treatment strategy. However, there is a lack of available data in the literature regarding serum UA levels in LP patients, particularly from India. Among existing reports, there are conflicting accounts of the association of UA levels among LP patients, as some found decreased levels of UA (12) (13) (14) suggesting oxidative stress, while others failed to find any difference (15) .
Prolactin (PRL) is a peptide hormone secreted by the anterior pituitary gland and many extra-pituitary sites, including immune cells, which plays important roles in reproduction, calcium metabolism, osmoregulation, and behavior (16, 17) . The relationship between PRL and the immune system has been demonstrated in many studies conducted over the last two decades. PRL has multiple immune-stimulatory effects and promotes autoimmunity. Although many studies have evaluated the clinical significance of PRL in different skin diseases, results have been conflicting (16, 18) .
Unlike other autoimmune diseases, there is paucity of available data in the literature regarding serum PRL levels in LP patients. Emotional disturbances are one of the most important causes of hyperprolactinemia (19) and stress is significantly associated with exacerbation of LP (20) , thus secondary hyperprolactinemia due to stress cannot be excluded. The aims of the present study were to determine whether LP was accompanied by changes in serum UA and PRL levels during exacerbation and remission of disease, and to identify correlations between LP and the emotional status of patients.
Materials and Methods
This hospital-based, case-control study was conducted in the Department of Oral Medicine and Radiology, Subharti Dental College, Meerut, Uttar Pradesh, India. The study protocol was approved by the institutional ethical committee (SDC/CER/2015) in the year 2015. All patients enrolled in the study group and the control group submitted informed consent prior to taking part in this investigation. The duration of the present study was 12 months and included 39 patients who were clinically diagnosed with oral LP. The clinical diagnostic criteria for oral lesions used in this study were as follows: i) the presence of keratotic, pinhead-sized, white, slightly elevated papules (papular LP), which may be discrete or arranged in reticular (reticular LP) or plaque-like (plaque-like LP) configurations; ii) atrophic LP, characterized by thinning of the epithelium leading to the appearance of atrophic red areas within the white lesions; iii) erosive (ulcerative) LP, characterized by areas of well-defined ulceration within the abovementioned lesions; and iv) bullous LP, characterized by the presence or development of bullous areas within the abovementioned lesions (1). In addition, 39 age-and sex-matched subjects who visited the Department of Oral Medicine and Radiology with minor ailments, such as dental caries, chronic generalized gingivitis, etc., served as controls.
Exclusion criteria included the use of any systemic steroids, immunosuppressive drugs, or nonsteroidal anti-inflammatory drugs within the last 4 weeks and the use of topical medications within the last 2 weeks. Other exclusion criteria included tobacco use, excessive alcohol consumption, pregnancy, lactation, a history of trauma or any surgery within 1 month prior to sampling, the presence of systemic diseases, including kidney and liver dysfunction, obesity, ketosis, familial hyperuricemia, gout, and blood dyscrasias, other dermatologic diseases affecting immune system, and any malignancy. Patients receiving any medications affecting PRL levels, such as phenothiazines (chlorpromazine), antidopaminergic agents (metoclopramide), antihypertensive agents (calcium channel blockers, methyldopa), histamine H2-receptor antagonists (cimetidine), and endocrinopathies, were also excluded.
Both LP patients and controls underwent a psychological evaluation using the Depression Anxiety Stress Scale-21 (DASS-21). Blood samples (5 mL) were collected between 10:00 and 12:00 h from all patients and controls enrolled in the study. Then, a second blood sample was collected from those in the study group only when there was evidence of clinical signs of remission after treatment with topical corticosteroids. Patients were considered to be in a stage of remission when there was no evidence of papules, striae, plaques, erosions, ulcers, bullae, or burning sensations, which are present in an exacerbated state. Serum UA was assayed using the Vitros 250 fully automated analyzer (Ortho Clinical Diagnostics, Linden, NJ, USA) by the uricase/peroxidase (colorimetric) method. Serum PRL levels were measured using the Vitek Immunodiagnostic Assay System (bioMérieux, Marcy-l'Étoile, France), an automated bench-top immuno-analyzer, based on enzyme-linked fluorescent assay technology.
Statistical analysis of the data was performed using the Statistical Package for Social Sciences (ver. 17.0; SPSS, Inc., Chicago, IL, USA). The t-test and chi square test were used for non-parametric values, and analysis of variance was used for all other data. A P value of <0.05 was considered to be significant and P < 0.001 was considered to be highly significant.
Results
The cohorts in this study included 39 LP patients (14 males and 25 females) and 39 age-and sex-matched controls aged 17-55 years. The age and sex distributions of the study and control groups are presented in Table  1 . The mean duration of symptoms in the study group was 7.7 months (range, 1-24 months). Reticular LP was the most common of the six subtypes of LP, accounting for 79.5% of cases. More than one subtype was found in 56.4% of cases. The erosive subtype was seen in 43.6% of cases, atrophic in 17.9%, plaque-like in 7.7%, papular in 2.6%, and bullae in 2.6%. The most common location of LP in the oral cavity was the buccal mucosa, which accounted for 87.2% of cases, followed by the buccal vestibule (51.3%), floor of the mouth (33.3%), tongue (20.5%), gingiva (10.2%), and palate (2.6%).
There was a significant difference in mean UA levels between the cases and controls aged less than 35 years (4.05 vs. 5.28 mg/dL, respectively, P = 0.002). However, there was no difference between cases and controls aged >35 years ( Table 2 ). The mean serum UA level was significantly increased after remission in LP patients aged <35 years as well as those aged >35 years, when compared to levels at presentation ( Table 3) .
As shown in Table 4 , there was no significant difference in mean serum PRL levels between LP patients and controls (17.65 ± 18.02 vs. 21.26 ± 10.23 ng/mL, respectively). After remission, the mean serum PRL level of LP patients was 15.64 ± 15.97 ng/mL. There was a significant difference between the mean of the two groups before and after treatment (Table 5) .
Patient sex and duration of symptoms were significant correlated with UA and PRL levels in the present study. Correlations between sex and serum PRL and UA levels are presented in Tables 6 and 7 , respectively. Correlations between duration of symptoms and serum PRL and UA levels are presented in Tables 8 and 9 , respectively.
The mean serum PRL levels were significantly higher in non-vegetarian patients in the diseased state as well as the remission phase, as compared to the controls. There were significant differences in depression and stress scores between the study and control groups. However, there was no significant difference in depression, anxiety, and stress scores between the study and control groups (Tables 10-12, respectively). Severe grades of depression (12.8%) and stress (15.4%) were seen only in the study group. There was no correlation between depression, anxiety, or stress scores, as assessed with the DASS-21, and UA levels in study population (Table 13) . PRL levels were significantly correlated with the anxiety scores of the DASS-21 among LP patients in both the exacerbation and remission phases (Table 14) .
Discussion
Free radicals and ROS play important roles in the pathogenesis of LP, which is an immune-mediated disease. The imbalance between the production of ROS and the ability of the biological system to detoxify reactive intermediates and easily repair the resultant damage constitutes oxidative stress (5,6). The primary defense against oxidative stress includes antioxidants, such as selenium, bilirubin, enzymes like catalase, superoxide dismutase, and glutathione peroxidase, as well as the vitamins C, D, and E, and the end-products of lipid peroxidation, such as monoaldehyde and UA (12) (13) (14) . UA was chosen for analysis in the present study because it is the most abundant antioxidant and accounts for up to 60% of serum-free radical scavenging capacity (11, 12) . Blood samples were collected between 10:00 and 12:00 h as PRL shows diurnal variation and increases in the early morning at around 08:00 h. There is no diurnal variation in serum UA levels (21, 22) . The time of blood collection was also set to correspond with the peak patient load in the department as maximum number of patients report between 10:00 and 12:00 h in the college. As a scavenger of free radicals, UA chelates metal ions, such as iron and copper, to prevent them from catalyzing free-radical reactions (23) . UA prevents the formation of peroxynitrite, which, in turn, prevents inactivation of cellular enzymes and modification of the cytoskeleton, as peroxynitrite is a reactive nitrogen species that adds nitrogen to the tyrosine residues of proteins. It also prevents the degradation of superoxide dismutase, an enzyme that clears superoxide from the cell. UA neutralizes cellular superoxide and prevents its reaction with nitric oxide to form peroxynitrite (24) . Measurement of serum UA is strongly indicative of the antioxidant capacity of blood and an indirect indicator of oxidative stress. Hence, UA has been studied in various diseases, including diabetes, cardiovascular diseases, multiple sclerosis, periodontal diseases, and LP (25,26).
Various studies have reported a very wide reference range of UA levels in LP. For example, Das et al. reported that serum UA ranged from 2.6 to 8.2 mg/dL in a healthy Assamese population (27) . In the present cohort, UA ranged from 2.4 to 6.2 mg/dL. As age can affect the serum concentration of UA and there was a wide variation in age among the subjects in the present study (16-55 years), cases and age-and sex-matched controls were divided into two age groups for statistical analysis. The first group included individuals aged <35 years and the second group included those aged ≥35 years. In the present study, there was a significant difference in the mean UA level between cases and controls, indicating higher levels of antioxidants in controls as compared to cases, but this difference only occurred in individuals aged <35 years, as there was no difference among individuals aged ≥35 years probably because serum UA increases with age (28) .
Previous studies have reported correlations between UA levels and sex. However, the results of the present study failed to establish any such correlation probably due to the small sample size and wide age range of the study participants.
The results of the present study indicated a pathological correlation between decreased UA levels with exacerbation of LP state when compared to healthy controls and those with LP in the remission phase. These results were consistent with those reported by Chakraborti et al. in an Indian population (12) . Other studies have reported a significant decrease in UA levels in LP patients in Italy and Iran (13, 14) .
Patients who participated in the present study were treated with topical corticosteroids. Corticosteroids are anti-inflammatory, anti-mitogenic, and immunosuppressant agents that act by reducing inflammatory mediators and recruitment of inflammatory cells, and thus have a role in reducing oxidative stress (29) . Also, oxidative stress is reported to be a significant component of behavioral and emotional diseases (30) . In the present study, more than 50% of the patients reported a sense of distress due to the discomfort caused by LP. There is psychological benefit of steroid therapy for patient in remission, as these agents can relieve discomfort. Since these factors may have affected serum UA levels, further studies with larger patient cohorts are needed to test this hypothesis (29, 30) .
Hormonal, immunomodulatory, and metabolic pathways play major roles in the development of LP. PRL has immune stimulatory effects and promotes autoimmunity. PRL levels have been correlated with disease activity in various autoimmune diseases, including systemic lupus erythematosus, rheumatoid arthritis, Sjogren's syndrome, Hashimoto's thyroiditis, multiple sclerosis, psoriasis, hepatitis C infection, Behçet's disease, peripartum cardiomyopathy, and active celiac disease (31) . The present study is one of the first to assess the role of PRL in LP.
PRL is produced by the pituitary gland as well as many immune cells that express the PRL receptor, particularly lymphocytes. PRL stimulates the immune response, interferes specifically with the induction of B cell tolerance, enhances proliferative responses to antigens and mitogens, and increases the production of immunoglobulins and cytokines, such as TNF-α, interferon-γ, IL-12, IL-1β, and autoantibodies. Interestingly, PRL itself is unable to initiate an immune reaction, as it is more of a factor that maintains homeostasis during immune reactions. Increased PRL serum levels have been described in several systemic as well as organ-specific autoimmune diseases, such as celiac disease and systemic lupus erythematosus, which might result from several factors, such as the increased release of PRL from the anterior pituitary due to inflammatory cytokines or reduced production of suppressive dopamine, or alternatively, increased production of PRL by immune cells (16, 18, 31, 32) . It is questionable whether pharmacotherapy is useful to decrease serum PRL levels in the treatment of autoimmune diseases. However, ongoing studies suggest it might be possible to use serum PRL level detection as a marker of a disease activity (32) . This hypothesis was tested for the first time in LP patients in the present study. The results showed a significant decrease in mean PRL levels during the remission phase of LP when compared to that during the exacerbation phase. However, there was no significant difference in mean PRL levels in LP patients in the exacerbation phase or in the control group, suggesting the existence of other confounding factors.
In the present study, serum PRL levels decreased after treatment with topical corticosteroids. A literature search revealed no effect of topical corticosteroids on PRL levels, although some studies reported a reduction in PRL secretion or decreased PRL levels after treatment with systemic steroids. If steroids are applied over large areas, systemic absorption may occur, which can affect PRL levels (33) . Release of PRL from the anterior pituitary can be decreased due to decreased production of inflammatory cytokines. Also, hyperprolactinemia has been reported in several psychological diseases, such as depression, anxiety, and stress. These studies found that the remission of anxiety symptoms was correlated with a decrease in serum PRL levels (33) .
It is well known that psychological factors trigger and exacerbate LP (20) . There is a bidirectional interaction between the skin and the mind. Psychologically, the skin is an erogenous zone and channel for emotional discharge. So, a skin disorder could be considered a manifestation of unexpressed anger or an inner conflict due to external stress (34) .
The DASS-21 is a self-reported measure of anxiety, depression, and stress developed by Lovibond and Lovibond. Depression, anxiety, and stress are three psychosocial stressors that are co-related, but have different features. Depression is characterized by low positivity, loss of self-esteem and incentive, dysphonic mood (e.g., feelings of sadness or worthlessness), and a sense of hopelessness. Anxiety is characterized by autonomic arousal and fearfulness (physiological hyper arousal), panic attacks, and fear (e.g., trembling or faintness). Depression and anxiety share the nonspecific factor of general distress. Stress is characterized by persistent tension, irritability, and a low threshold for becoming upset or frustrated (negative affect), and a tendency to overreact to stressful events (35) . Any one of these three components can lead to psychological distress, thus any component can precipitate a dermatological or mucosal disorder, such as LP, or can lead to changes in levels of hormones associated with psychological distress, such as PRL (19) . This could also explain the correlation of anxiety score with PRL in the present study.
In the present study, the results of the DASS-21 showed a significant difference in depression and stress scores among the patients and controls, but not anxiety scores. Similar results were obtained for all three psychological stressors (i.e., anxiety, depression, and stress) among LP patients in a study conducted by Chaudhary et al. Emotional disturbances are among the most important causes of hyperprolactinemia (19) , which is significantly associated with exacerbation of LP. Thus, secondary hyperprolactinemia due to psychological distress cannot be excluded. In the present study, the anxiety score of the DASS-21 was significantly correlated with PRL levels in LP patients both during the exacerbation and remission phases. There was, however, no correlation of PRL levels with depression and stress scores. Thus, the results of the present study only identified a correlation of PRL with disease activity and the emotional status of patients. On the contrary, in a study of chronic orofacial pain, Hampf et al. found no correlation between the expression of the endocrine markers PRL and cortisol with the severity of pain or mental disturbance (38) .
One of the major limitations to the present study was the small sample size and wide age variation among the participants. A second limitation was that only one antioxidant (i.e., UA) was considered. Diet and body mass can also affect serum UA levels. Potential differences in serum UA and PRL levels between the different subsets of LP (i.e., reticular, papular, plaque-like, bullous, atrophic, and erosive) were not tested because of the low number of patients in the individual subsets.
Despite these limitations, the results of the present study indicate that UA is an important, promising antioxidant marker for LP. As these findings point to a decrease in the antioxidant UA, the problem of oxidative stress in LP should also be further investigated in a larger number of patients by assessing other markers of oxidative stress and antioxidants.
The results of the present study suggest that UA should be considered as a useful biomarker of antioxidant status in LP for elaboration of treatment strategy and monitoring. The low UA level of LP patients may be an outcome of associated depression, anxiety, and stress. Although serum PRL levels may not be as significant in LP as in other autoimmune diseases, further studies are warranted to confirm these results. As serum PRL was increased in patients with anxiety, PRL may offer a novel therapeutic target in skin diseases that worsen in response to psychological stress.
